The endoscopic retrograde cholangiopancreatography market size was valued at USD 2.33 billion in 2025 and is projected to grow from USD 2.52 billion in 2026 to USD 4.74 billion by 2034 at a CAGR of 8.21% during the forecast period 2026-2034. North America dominated the endoscopic retrograde cholangiopancreatography market with a market share of 38.6% in 2025.
Endoscopic retrograde cholangiopancreatography (ERCP) is a minimally invasive medical procedure used to diagnose and treat disorders of the bile ducts, pancreas, and gallbladder. It combines endoscopy and X-ray imaging to detect and manage conditions such as gallstones, bile duct blockages, tumors, and pancreatic diseases. Demand is growing due to the increasing prevalence of gastrointestinal disorders, advancements in endoscopic technology, and the rising preference for minimally invasive treatments.
Download a Free Sample To learn more about this report,
Growing Adoption of Advanced ERCP Devices for Minimally Invasive Biliary Treatment
Endoscopic Retrograde Cholangiopancreatography Market trends are being driven by the increasing preference for minimally invasive procedures to diagnose and treat disorders of the bile ducts and pancreas. Hospitals are expanding the use of advanced duodenoscopes, guidewires, stents, and stone retrieval devices to improve procedural accuracy and reduce recovery time. The rising incidence of gallstones, pancreatic disorders, and biliary tract diseases is also increasing the demand for ERCP procedures. Improvements in endoscopic imaging and therapeutic accessories are helping physicians perform complex interventions more safely and efficiently. These developments are supporting endoscopic retrograde cholangiopancreatography market growth as healthcare providers continue adopting advanced gastrointestinal technologies.
Rising Innovation in Single-Use Endoscopes and AI-Assisted Imaging
Endoscopic Retrograde Cholangiopancreatography Market trends are also being influenced by the growing adoption of single-use endoscopes and artificial intelligence-enabled imaging systems. Disposable duodenoscopes are helping reduce the risk of cross-contamination while simplifying infection control in hospitals. At the same time, AI-assisted imaging technologies are improving the detection of abnormalities and supporting more accurate clinical decision-making during ERCP procedures. These innovations are strengthening endoscopic retrograde cholangiopancreatography market share by enhancing procedure safety, improving diagnostic confidence, and supporting better patient outcomes.
Increasing Preference for Minimally Invasive Biliary and Pancreatic Procedures
The endoscopic retrograde cholangiopancreatography market is growing as hospitals increasingly prefer minimally invasive procedures for diagnosing and treating pancreatic and biliary disorders. ERCP allows physicians to remove bile duct stones, place stents, and treat blockages without the need for open surgery, helping patients recover faster and spend less time in the hospital. The rising number of gallstone cases, pancreatic diseases, and gastrointestinal disorders is strengthening endoscopic retrograde cholangiopancreatography market demand. Growing awareness of early diagnosis and better access to advanced endoscopy services are also supporting market growth.
High Procedure Costs and Limited Availability of Skilled Specialists
The endoscopic retrograde cholangiopancreatography market faces challenges because ERCP procedures require specialized equipment, advanced imaging systems, and highly trained gastroenterologists. The cost of the procedure can be high, especially in regions with limited healthcare funding. In addition, possible complications such as pancreatitis, bleeding, and infections require careful patient selection and experienced clinical teams.
Advancements in Endoscopic Imaging and Single-Use Devices
The endoscopic retrograde cholangiopancreatography market offers strong opportunities as manufacturers continue to develop high-definition imaging systems, disposable endoscopes, and advanced therapeutic devices. These innovations improve visualization, reduce the risk of infection, and help physicians perform more precise procedures. Growing healthcare investments and the expansion of specialized endoscopy centers are expected to strengthen endoscopic retrograde cholangiopancreatography market share over the coming years.
Maintaining Consistent Clinical Outcomes in Complex Cases
The endoscopic retrograde cholangiopancreatography market continues to face challenges because procedure success depends on physician expertise, patient condition, and the complexity of biliary or pancreatic disorders. Hospitals must ensure access to experienced specialists while maintaining advanced endoscopy equipment and strict infection control standards. Manufacturers also need to improve device reliability and simplify complex procedures. Continued investment in physician training, product innovation, and advanced imaging technologies will be essential for long-term market growth.
Request Customizationto receive a tailored report.
Endo Therapy Devices Segment Dominated the Market with 43.8% Share in 2025
The endo therapy devices segment dominated the global endoscopic retrograde cholangiopancreatography market with a 43.8% share in 2025. These devices are widely used during ERCP procedures for stone removal, stent placement, tissue sampling, and other therapeutic interventions. The growing preference for minimally invasive procedures and the increasing number of biliary and pancreatic disorders continue to support the segment's leading position.
The endoscopes and visualization systems segments are also growing steadily. Endoscopes remain essential for accessing and examining the biliary and pancreatic ducts, while advanced visualization systems help physicians perform procedures with greater accuracy and improved image quality. Their continuous technological improvements are supporting wider adoption across healthcare facilities.
The energy devices and others segments also continue to expand as hospitals adopt advanced equipment for precise tissue cutting, coagulation, and other specialized ERCP procedures. Ongoing innovation in endoscopic technologies is expected to support growth across all product categories.
Biliary Stenting Segment Dominated the Market with 24.8% Share in 2025
The biliary stenting segment dominated the global endoscopic retrograde cholangiopancreatography market with a 24.8% share in 2025. Biliary stenting is widely performed to relieve bile duct blockages caused by gallstones, tumors, or strictures. The increasing number of biliary diseases and the growing preference for minimally invasive treatment continue to drive demand for this procedure.
The biliary sphincterotomy, pancreatic duct stenting, and biliary dilatation segments are also witnessing steady growth. These procedures are commonly performed to improve bile flow, remove stones, and treat narrowing of the bile ducts. Their effectiveness in managing complex pancreatic and biliary conditions continues to support their adoption.
The pancreatic sphincterotomy, pancreatic duct dilation, and endoscopic retrograde procedures also continue to grow as physicians increasingly rely on advanced ERCP techniques for accurate diagnosis and treatment. Improvements in endoscopic devices and procedural techniques are expected to support growth across all procedure segments.
Hospitals Segment Dominated the Market with 74.6% Share in 2025
The hospitals segment dominated the global endoscopic retrograde cholangiopancreatography market with a 74.6% share in 2025. Hospitals perform the majority of ERCP procedures because they have specialized gastroenterologists, advanced imaging equipment, and comprehensive surgical facilities to manage complex biliary and pancreatic conditions. Rising patient admissions and increasing availability of advanced endoscopy units continue to strengthen this segment.
The outpatient facilities segment is also growing steadily as more minimally invasive ERCP procedures are being performed in specialized outpatient centers. These facilities offer shorter recovery times, lower treatment costs, and greater convenience for eligible patients, making them an increasingly attractive option.
Growing awareness of early diagnosis, advances in endoscopic technologies, and the increasing preference for minimally invasive gastrointestinal procedures are expected to support demand across both hospitals and outpatient facilities.
Speak to an Analystto discuss market opportunities.
North America endoscopic retrograde cholangiopancreatography market accounted for 38.6% of the global market, reaching USD 0.90 billion in 2025, and is projected to grow at a CAGR of 7.4% during the forecast period. The market is growing steadily because of the increasing number of gastrointestinal disorders, rising demand for minimally invasive procedures, and wider adoption of advanced endoscopy systems. Strong healthcare infrastructure and ongoing technological advancements are also supporting market growth.
The U.S. market was valued at USD 0.77 billion in 2025, making it the largest contributor in North America. Growing demand for minimally invasive gastrointestinal procedures, increasing prevalence of pancreatic and biliary disorders, and continuous investment in advanced endoscopy technologies continue to drive market growth.
Canada's market reached USD 0.13 billion in 2025. Rising healthcare spending, increasing awareness of digestive diseases, and expanding access to advanced diagnostic and therapeutic procedures continue to support steady market growth.
Europe endoscopic retrograde cholangiopancreatography market accounted for 27.2% of the global market, reaching USD 0.63 billion in 2025, and is expected to register a CAGR of 7.1% during the forecast period. Increasing cases of biliary and pancreatic diseases, growing preference for minimally invasive treatments, and well-developed healthcare systems are supporting market growth. Continued investment in advanced endoscopic equipment is also contributing to regional expansion.
Germany's market accounted for USD 0.18 billion in 2025. Strong healthcare infrastructure, increasing use of advanced endoscopy systems, and growing demand for gastrointestinal procedures continue to support market growth.
The UK market was valued at USD 0.13 billion in 2025. Rising awareness of digestive health, expanding endoscopy services, and increasing adoption of minimally invasive procedures continue to contribute to market growth.
Asia Pacific endoscopic retrograde cholangiopancreatography market accounted for 23.8% of the global market, valued at USD 0.55 billion in 2025, and is projected to register a CAGR of 9.2% during the forecast period. Improving healthcare infrastructure, increasing diagnosis of gastrointestinal disorders, and rising demand for advanced endoscopic procedures are driving market growth across the region. Expanding healthcare access and growing investments in medical technology are also creating new opportunities.
Japan's market generated USD 0.10 billion in 2025. An aging population, advanced healthcare facilities, and increasing demand for minimally invasive gastrointestinal treatments continue to support market growth.
China's market accounted for USD 0.29 billion in 2025, representing the largest share within Asia Pacific. Rising healthcare investments, increasing prevalence of digestive diseases, and expanding hospital infrastructure continue to drive market growth.
Latin America endoscopic retrograde cholangiopancreatography market accounted for 6.1% of the global market, reaching USD 0.14 billion in 2025, and is projected to grow at a CAGR of 7.6% during the forecast period. Improving healthcare services, increasing awareness of gastrointestinal diseases, and expanding access to advanced endoscopic procedures are supporting market growth across the region.
Brazil's market reached USD 0.07 billion in 2025. Rising healthcare investments, growing availability of endoscopy services, and increasing demand for minimally invasive treatments continue to create growth opportunities.
Middle East & Africa endoscopic retrograde cholangiopancreatography market accounted for 4.3% of the global market, totaling USD 0.10 billion in 2025, and is anticipated to grow at a CAGR of 7% during the forecast period. Growing healthcare investment, improving access to specialized gastrointestinal care, and increasing adoption of advanced endoscopy technologies are supporting market growth across the region.
The UAE market was valued at USD 0.04 billion in 2025. Government investment in advanced healthcare facilities, increasing demand for minimally invasive procedures, and expanding gastroenterology services continue to support market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com